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InﬂammationThe serum amyloid A (SAA) family of proteins is encoded by multiple genes, which display allelic
variation and a high degree of homology in mammals. The SAA1/2 genes code for non-glycosylated
acute-phase SAA1/2 proteins, that may increase up to 1000-fold during inﬂammation. The SAA4 gene,
well characterized in humans (hSAA4) and mice (mSaa4) codes for a SAA4 protein that is glycosylated
only in humans. We here report on a previously uncharacterized SAA4 gene (rSAA4) and its product in
Rattus norvegicus, the only mammalian species known not to express acute-phase SAA. The exon/intron
organization of rSAA4 is similar to that reported for hSAA4 and mSaa4. By performing 50- and 30RACE, we
identiﬁed a 1830-bases containing rSAA4 mRNA (including a GA-dinucleotide tandem repeat). Highest
rSAA4mRNA expression was detected in rat liver. In McA-RH7777 rat hepatoma cells, rSAA4 transcription
was signiﬁcantly upregulated in response to LPS and IL-6 while IL-1a/b and TNFa were without effect.
Luciferase assays with promoter-truncation constructs identiﬁed three proximal C/EBP-elements that
mediate expression of rSAA4 in McA-RH7777 cells. In line with sequence prediction a 14-kDa non-
glycosylated SAA4 protein is abundantly expressed in rat liver. Fluorescence microscopy revealed
predominant localization of rSAA4-GFP-tagged fusion protein in the ER.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction clinical use [5]. A-SAA acts as precursor protein for reactive sys-The synthesis of acute-phase proteins is largely regulated by
inﬂammation-associated cytokines, peptide hormone signals
produced by endothelial cells, lymphocytes, and activated mono-
cytes/macrophages. Serum amyloid A (SAA) is a generic term for
a family of acute-phase proteins coded for by different genes with
a high degree of homology in mammals [1,2].
In humans and mice, SAA1 and SAA2 genes are best character-
ized sharing approx. 95% overall sequence identity [3,4]. The differ-
ent alleles of the SAA1/2 loci encode non-glycosylated acute-phase
SAA (A-SAA) 1/2 proteins (104-amino acids [aa], 12-kDa). A-SAA
may reach plasma levels 1000-fold greater than that found in the
non-inﬂammatory state, thus representing an ideal marker fortemic amyloid A (AA) amyloidosis [6] and modulates the athero-
protective properties of high-density lipoproteins (HDL) during
inﬂammation [7]. Other activities, e.g. interaction with various
receptors that modulate cytokine release and intracellular signal-
ling pathways, activation of transcription factors and production
of matrix metalloproteinases, underline a potential role of A-SAA
in atherogenesis, coronary syndrome, and tumor pathogenesis
[8–10]. While human SAA3 (hSAA3) is considered a pseudogene,
the murine Saa3 (mSaa3) homolog codes for mSAA3 protein.
In humans and mice, the SAA4 locus contains the gene encoding
for a unique SAA family member assumed to be constitutively
expressed [11,12]. The SAA4 gene differs from SAA1/2, whose four
exons and three introns share in between 93 and 100% and 87
and 92% identity. The hSAA4 protein (14-kDa) shares approx. 55%
identity with SAA1/2. Due to an octapeptide insertion, hSAA4
consists of 112-aa. A N-linked glycosylation site in this octapeptide
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conditions hSAA4 constitutes more than 90% of total SAA [13]; it
associates with very low-density lipoproteins and HDL [13]. In
contrast to A-SAA, SAA4 does basically not act as the precursor
molecule for AA ﬁbrils, and levels do not change dramatically
during the acute-phase response [14].
Contrary to all mammalian species studied, the rat lacks expres-
sion of A-SAA proteins [15]. Consequently, rats do not develop AA
amyloidosis [15], a disease in which ﬁbrils formed from the 76-aa
N-terminal portion of A-SAA induce severe organ dysfunction.
We here present ﬁrst evidence on characterization of mRNAs for
rat SAA4 (rSAA4), abundant expression of rSAA4 in the liver on
mRNA and protein level, and its cellular localization.2. Materials and methods
2.1. Rapid ampliﬁcation of cDNA ends (RACE)
Rat brain Marathon-Ready cDNA (Clontech Laboratories, Takara
Bio Company, Mountain View, CA) was used as template to amplify
full-length rSAA4 cDNA (Supplemental Table I). Primers used for the
ampliﬁcation of the 50 and 30cDNA ends are given in Supplemental
Table II. RACE products were cloned into a pCR2.1-Topo vector
(Life-Technologies Ltd., Invitrogen, Paisley, UK) and transformed
into TOP10 One Shot Cells (Life-Technologie). After transformation
plasmid DNA was isolated using Qiagen Plasmid Mini Kit (Qiagen,
Hilden, Germany) and sequenced with vector-speciﬁc M13 and
rSAA4-speciﬁc primers (Supplemental Table II). After dye termina-
tor removal with Centri-Sep spin columns (Princeton Separations,
Freehold, NJ) sequencing reactions were analyzed with a 3100
Genetic Analyzer (Life-Technologies™, Foster City, CA).
2.2. RNA isolation, DNase-I digestion and reverse-transcription
Sprague–Dawley rats (200–300 g body weight; Himberg,
Austria) received an i.p. injection of 2 mg/kg LPS (Escherichia coli,
Serotype 055:B5; Sigma–Aldrich, St. Louis, MO) or vehicle (PBS).
The study was approved by the ethics committee of the Federal
Ministry of Science, Austria [GZ 66.010/9-Pr/4/2002] carried out
in line with the European Communities Council Directive. After
48 h rats were killed with an overdose of sodium pentobarbital
and tissues were kept either in N2 or at 25 C (in case of pancreas,
colon, and lungs) in 1 ml RNA Later Reagent (Life-Technologies).
Using Trizol reagent (Life-Technologies) or RNeasy-Minikit
(Qiagen) total RNA was isolated from rat tissues and McA-
RH7777 cells. One lg of RNA was digested with DNase-I and
reverse-transcribed using random hexamer primers and
SuperScript II Reverse Transcriptase (Life-Technologies) [16].
2.3. qPCR-analysis
qPCR-assays were performed using Power SybrGreen Master-
mix, ABI Prism 7000 SDS instrument (Life-Technologies) and
respective primers (Supplemental Table III). Fold-change in gene
expression of the target gene compared to rGAPDH was calculated
by the 2DDCT method and absolute mRNA expression (copy
number) was determined by the equation of a calibration curve.
2.4. Protein isolation and Western blot analysis
Frozen rat tissues were immersed in extraction buffer (Supple-
mental Table IV) and homogenized with Ultraturrax (Ika GmbH,
Staufen, Germany). Lysates were centrifuged and supernatants
were subjected to Western-blot analysis [16]. Membranes were
incubated with anti-human SAA4 peptide (aa-position 94–112)rabbit antiserum (dilution 1:2500) [17]. As positive controls, hSAA4
[18] and tagged-hSAA4 [17] (both expressed in E. coli) were used.
2.5. Cell culture experiments
McA-RH7777 hepatoma cells (ATCC) were grown in DMEM
(Supplemental Table IV) at 37 C in 5% CO2. Cells, seeded in 6-well
plates, were incubated in DMEM containing 10 ng/ml IL-1a/b, IL-6,
TNFa (R&D Systems Inc., Minneapolis, MN) or 1 lg/ml LPS (Sigma–
Aldrich) for 12–60 h.
2.6. Cloning of rSAA4pcDNA3.1/CT-GFP-TOPO vector and transfection
of McA-RH7777 cells
To obtain a full-length rSAA4-GFP fusion protein a PCR was
performed using rSAA4-cloning primers including the native
Kozak-sequence (Supplemental Table V) and rat liver cDNA as
template (Supplemental Table VI). The PCR-product was separated
by gel electrophoresis and puriﬁed using Wizard SV Gel- and PCR-
Clean-Up System (Promega, Madison, WI).
cDNA for rSAA4 was cloned into pcDNA3.1/CT-GFP-TOPO vector
(Life-Technologies) and McA-RH7777 cells (seeded on glass plates
in 6-well-dishes, 70% conﬂuence) were transfected using
ExGen-500 in vitro Transfection Reagent (Fermentas, St. Leon-
Rot, Germany). After 6 h, 1 ml of culture medium was added and
incubated for 20 h.
2.7. Confocal imaging
Cells were incubated with 1 ml of a loading solution (Supple-
mental Table IV) containing 0.5 lM ER-Tracker Red or 0.1 lM
Mito-Tracker Red (Life Technologies Ltd.) for 5 or 40 min. GFP sig-
nals were imaged together with ER-Tracker Red or Mito-Tracker
Red using a Nipkow-disk-based array confocal laser scanning
microscope (Supplemental material section).
2.8. Luciferase assay
In silico analysis of rSAA4 promoters was performed with the
Genomatix software package version 7.0. Gene2promoter was used
to search for vertebrate promoter sequences of SAA4 and MatIn-
spector to identify transcription factor binding sites and their posi-
tion and orientation towards each other.
2.8.1. Mutagenesis of the full-length rSAA4 promoter fragment (ﬂ-
rSAA4)
The sequence +44 to 3293 bp relative to the transcription start
codon of rSAA4 was cloned in pGL3 Basic vector (Promega) to cre-
ate ﬂ-rSAA4. Primers were designed with 15 bp homologous to the
multiple cloning site of pGL3 with restriction enzyme binding sites
to enable cloning of the rSAA4 promoter fragment into pGL3 (Sup-
plemental Table VII).
PCR-ampliﬁcation of the ﬂ-rSAA4 promoter fragment was per-
formed using the BAC clone CH230-458A11 (BACPAC resources
center, Oakland, CA) as template (Supplemental Table VI). The
PCR-products were puriﬁed using the Nucleospin II kit (Macherey
& Nagel GmbH & Co. KG, Düren, Germany) and ligated with the
In-Fusion Dry-Down PCR-Cloning Kit (Clontech-Laboratories) to
create the recombinant ﬂ-rSAA4 vector. After transformation posi-
tive clones were identiﬁed with colony-PCR, restriction analysis
and DNA sequencing.
To test the activity of the three C/EBP-elements most proximal
to the start codon a deletion of the BOX (C/EBP-element 1–3
ﬂanked by FAST and HOXF binding sites, 889 to 1166 bp) was
performed to create construct A. Mutagenesis was performed with
the Phusion Site-Directed Mutagenesis Kit (Thermo-Fisher-
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(Supplemental Tables VI and VIII). The PCR-product was separated
from unmutated, non-linearized template vector by agarose gel
electrophoresis and isolated with the Nucleospin II Kit. For
circularization, 20 ng linearized vector was ligated with T4
DNA-Ligase (Fermentas), transformed into E. coli Fusion-Blue cells
(Clontech-Laboratories). Positive clones were identiﬁed by colony-
PCR and DNA-sequencing.
2.8.2. Cloning of rSAA4 promoter fragments
Deletions constructs were created to further investigate the
three proximal C/EBP- elements: B (+44 to 1084), C (+44 to
1113), D (+44 to 2449), and E (+44 to 932). Promoter frag-
ments of rSAA4 were PCR-ampliﬁed using the respective synthetic
oligonucleotides (Supplemental Table VII) and the BAC-clone
CH230-458A11 (BACPAC resources center) as template.
2.8.3. Luciferase reporter assay
Cells (80% conﬂuence) were transfected with 2 lg of the respec-
tive pGL3 construct (expressing Fireﬂy Luciferase) and 4 ng of the
control plasmid pRL-TK (expressing Renilla Luciferase) using
ExGen-500 in vitro Transfection Reagent (Fermentas) according
to manufacturer’s suggestion. Cells were lysed and Luciferase
activity was measured using the dual-Luciferase reporter assay
(Promega) on a luminometer (Lumat-LB9501, Berthold-Technolo-
gies GmbH & Co. KG, Bad Wildbad, Germany). To account for
non-speciﬁc effects on reporter plasmids, experimental results
were expressed as normalized ratios. The ratio of Renilla and
Fireﬂy-Luciferase activity of each experiment was normalized
against cells transfected with the empty Luciferase vector.Fig. 1. Gene structure of rSAA4. (A) Rat SAA4 mRNAs (BC088188, AY325132, AY325161) fro
( ) represent untranslated regions, broad grey squares ( ) represent translated regions;
the gene. (B) Exon/intron structure of spliced ESTs published in the UCSC Genome Browse
are shown. (C) Schematic representation of results obtained by RACE: 30RACE product ex
50RACE product extends the 30-region of BC088188 and conﬁrms the 30UTR represented
from the ﬁrst coding exon of rSAA4 reaching to a primer located 2 exons upstream of rSA
product was unsuccessful using rat Marathon cDNA as template and standard PCR pro
represent untranslated regions, broad black squares (j) represent translated regions, in
repeat (GA)n within the 50UTR of rSAA4 is indicated below. (F) Partial 50UTR of the SAA4
dinucleotide tandem repeat is only present in the rat genome. The UCSC Genome Brow2.9. Statistical analysis
Statistical analysis of qPCR data was performed by one-way
ANOVA and of Luciferase-Assay by Student’s t-test (unpaired,
two-tailed). Means were considered as signiﬁcantly different at
p < 0.05.3. Results
To determine the genomic structure of the rSAA4 gene and the
corresponding full-length rSAA4 cDNA, we performed 50- and
30RACE using a rat cDNA library as template. These experiments
showed an exon/intron organization for rSAA4 consisting of one
untranslated 50exon followed by three translated exons (Fig. 1).
The exon/intron organization of rSAA4 is similar to that reported
for hSAA4 and mSaa4 [12,19]. The 50RACE experiments (Fig. 1C) in
combination with reported ESTs (e.g. FQ107900, Fig. 1B) revealed
that the maximal 50UTR exceeds the reported RefSeq for rSAA4
(NM_001009478.1) by 90-bases (Supplemental Table IA–C).
Within this region, we found a GA-dinucleotide tandem
repeat with 23 repeats in the RefSeq sequence for rSAA4
(NM_001009478.1) (Fig. 1E and F). The sequence of this accession
number is based on the cDNA clone MGC:108857.
Performing 30RACE, we were able to reveal a maximum size of
the 30UTR of 1214-bases. This observation parallels the current ver-
sion of rSAA4 mRNA (BC088188-NM_001009478.1). We conclude
that the full-length sequence of rSAA4 mRNA consists of 1830-
bases (Supplemental Table IC).
To test the possibility of a read-through transcription between
rSAA4 and the neighboring HPS5 gene (NM_001135612.1) indi-m GenBank (http://www.ncbi.nlm.nih.gov/genbank/) are shown; thin grey squares
intronic sequences are shown as thin black lines. Arrowheads indicate orientation of
r with the most extended 50UTR (FQ107900) and 30UTR region (EX492688) of rSAA4
tends the 50UTR of EX492688 with 574 bases; that conﬁrms the 50UTR of BC088188;
by the spliced EST FQ107900. (D) The predicted PCR-product for primers spanning
A4 within a conserved exonic region of AY325132. PCR-ampliﬁcation of the 190 bp
grams. (E) Deduced full-length rSAA4 from RACE is shown: thin black squares ( )
tronic sequences are shown as thin black lines. The location of the GA-dinucleotide
gene in different mammalian species (i.e. rSAA4, mSAA4, and hSAA4): note the GA-
ser [29] was used.
1646 C. Rossmann et al. / Biochemical and Biophysical Research Communications 450 (2014) 1643–1649cated by the rat mRNA sequences AY325132 and AY325161
(Fig. 1A), a PCR spanning from the coding region of rSAA4 to a
highly conserved exon of AY325132 (Fig. 1D) was performed using
the Marathon rat brain cDNA as template. We observed no PCR-
product indicating that these read-through mRNAs are not
expressed in rat brain.
Next we analyzed rSAA4mRNA expression in various organs/tis-
sues revealing highest expression in liver, lung, heart, spleen and
kidney (Fig. 2A). This is comparable to expression patterns in the
mouse [11]. Injection of LPS did not alter rSAA4 mRNA expression
levels in all organs/tissues investigated (Fig. 2A).
Due to the striking homology of rSAA4 with hSAA4/mSAA4
(Supplemental Fig. I), an antibody raised against the C-terminal
portion (that differs from SAA1/2) of hSAA4 was used. The antise-
rum recognizes non-glycosylated hSAA4 (14-kDa [18], Fig. 2B [lane
1]) and non-glycosylated tagged hSAA4 (17-kDa [17], Fig. 2B [lane
2], Fig. 2C [lane 1]), and a 14-kDa band in rat liver (Fig. 2C [lane 2]).
This ﬁnding parallels data obtained in murine liver where no gly-
cosylated mSAA4 protein is present. No immunoreactive bands
for a 14-kDa protein were detected in other organs/tissues used
for mRNA expression proﬁling (Fig. 2A).
We then investigated whether cytokine-treatment could modu-
late rSAA4 transcription in McA-RH7777 cells. Highest induction
(up to 9-fold) was found in IL-6-treated cells between 24 and
36 h. Other cytokines did not signiﬁcantly alter rSAA4 mRNA
expression within 60 h (Fig. 3A). In contrast to the in vivo situation
(Fig. 2A), where rSAA4mRNA seems to be constitutively expressed,Fig. 2. Expression of rat and human SAA4. (A) Organs/tissues of control and LPS-treated ra
Absolute rSAA4 mRNA expression was determined with a calibration curve. Non-treated
[n = 6] and liver [n = 5]). Equal amounts of non-glycosylated recombinant hSAA4 (r-hSAA
liver (C) was subjected to Western-blot analysis using anti-human SAA4-peptide antiseLPS-treatment signiﬁcantly induced rSAA4 mRNA in McA-RH7777
cells (up to 4-fold) at almost all time points.
As basal levels of rSAA4mRNA in McA-RH7777 cells are low, we
failed to detect rSAA4 by Western-blots. Therefore a full-length
rSAA4-GFP fusion protein was overexpressed. Fluorescence
microscopy revealed predominant localization of this fusion
protein in the ER (Fig. 3B).
Previous studies have shown that the C/EBP-family of transcrip-
tion factors plays important roles in the expression of rSAA1
[20,21]. As disruption of hepatic C/EBPa in mice is paralleled by
massive down-regulation of mSaa4 mRNA [22] we hypothesized
that a C/EBP-element could be responsible for SAA4 mRNA expres-
sion in rats. To investigate the regulation of the rSAA4 gene we per-
formed in silico promoter analysis of a region approx. 3000 bp
upstream of the start codon using the Genomatix software [23],
predicting ﬁve C/EBP-elements (Fig. 4A); two are far distal from
the start codon, whereas three others are located more proximal
(<1.200 bp). To test the activity of these elements we cloned a ser-
ies of promoter constructs in a Luciferase-reporter vector (Fig. 4A).
Deleting the three most proximal C/EBP-elements between 888
and 1167 bp (construct A) leads to reduced Luciferase-activity
by approx. 90% (Fig. 4B). This suggests that the BOX (containing
C/EBP-element-1/-2/-3 ﬂanked by FAST and HOXF sites) is required
for maximal promoter activity. To investigate the proximal
elements C/EBP-element-1/-2/-3 within the BOX in more detail
we surveyed truncation constructs for their capacity to regulate
Luciferase activity. A proximal segment containing a singlets (48 h) were excised, RNA was isolated, reverse transcribed and subjected to qPCR.
(controls, n = 5) and LPS-treated rats (n = 7; except for lung, heart, thymus, kidney
4) (B) and tagged-r-hSAA4 (tr-hSAA4) (B/C) or protein lysate (65 lg/lane) from rat
rum as a primary antibody. One representative experiment is shown.
Fig. 3. Cytokine- and LPS-induced expression of rSAA4 in McA-RH7777 cells and intracellular localization of rSAA4-GFP-fusion protein. (A) Cells were treated with cytokines or LPS
for indicated time periods. RNA was isolated, reverse transcribed and subjected to qPCR. rSAA4 expression levels were normalized to rGAPDH (⁄p < 0.05, ⁄⁄p < 0.01,
⁄⁄⁄p < 0.001). Results are derived from two independent experiments performed in duplicate. ns, non-stimulated cells. (B) Intracellular localization of the GFP-tagged rSAA4
protein by confocal laser-scanning microscopy: green (GFP), red (ER or Mito-Tracker), yellow (colocalization). The bar represents 5 lm. (For interpretation of the references
to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 4. Luciferase assay of rSAA4 promoter constructs in McA-RH7777 cells. (A) Overview of the rSAA4 promoter (+44 and 3293 bp relative to the start codon) and the rSAA4
promoter deletion constructs. Deletion of the BOX (between 888 and 1167 bp; containing the three proximal C/EBP response elements and ﬂanked by FAST and HOXF
binding sites) resulted in the generation of construct A. Construct B–D contained the one, two, and three most proximal C/EBP binding sites, yielding starting points at 1084
(construct B), 1113 (construct C), and2449 (construct D), respectively. (B) Cells were transfected with 2 lg of the respective rSAA4 promoter construct and with 4 ng of the
control plasmid pRL-TK. Twenty-four hours after transfection cells were lysed and Fireﬂy and Renilla luminescence was quantiﬁed. Results are derived from four (construct B/
D) or three (construct A/C) independent experiments performed in triplicate. Results were normalized to the empty Luciferase vector (pGL3; ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001).
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evoke increased Luciferase activity >2-fold in comparison to
the control vector (Fig. 4B). Of note, we detected an additional
increase in Luciferase activity (approx. 50%) in an even shorter
proximal promoter fragment containing HOXF but no predicted
C/EBP-element-1 (+44 to 932 bp, construct E, data not shown).
The promoter fragment containing C/EBP-element-1 and -2 (+44
to 1113 bp, construct C) exhibited a signiﬁcant increase over
construct B (approx. 3.9-fold over pGL3). A promoter fragmentcontaining all three proximal C/EBP-elements plus additional
1000 bp (+44 to 2449 bp, construct D) showed increased
Luciferase-activity compared to pGL3 but decreased activity
compared to construct B/C, indicating binding of potential
repressive factor(s) between 1114 and 2449 bp. In summary,
Luciferase assays suggest a strict requirement of the BOX-
sequence for rSAA4 promoter activity and argue for a positive
effect of the predicted proximal C/EBP-elements in McA-
RH7777 cells.
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In contrast to humans, mice and other mammals, no A-SAA pro-
tein has been found to be associated with acute-phase HDL isolated
from rats [24]. Meek and Benditt [24] reported two SAA-related
genes (rSAA1, rSAA2) with striking homology to human and murine
SAA1/2. Both genes were upregulated in the liver but not in extra-
hepatic tissues in response to LPS. However, rSAA1/2 mRNA lack a
sequence coding for 50-aa of the N-terminus of the predicted A-
rSAA protein. Thus, it is obvious that rats, lacking A-SAA, do not
develop secondary reactive AA amyloidosis [24]. Although rSAA3
mRNA has been identiﬁed [24], it is still unknown whether rats
do express SAA4 mRNA and protein. We here characterized a novel
SAA4 gene in the rat.
Basically, the exon/intron structure of rSAA4 is similar to hSAA4
and mSaa4. In addition to the 50UTR and signal peptide, the com-
plete sequence encoding 1–112-aa (as found in humans and mice)
was determined. However, observations that the maximal 50UTR
exceeds the published rat RefSeq for rSAA4 (NM_001009478.1) by
90 bases (containing a GA-dinucleotide tandem repeat with 23-
repeats) is unique. This tandem repeat is only present in the rat
genome. Different repeat numbers found in rat ESTs (18- and 22-
repeats) and also in our cloned 50RACE products (9- and 10-
repeats) indicate that this tandem repeat might be a result of dif-
ferent allelic variations. Whether the length of this repeat modu-
lates rSAA4 expression remains to be elucidated.
The regulation of acute-phase genes in the rat by inﬂammatory
mediators represents an excellent model to study the interplay
between transactivators and transrepressors on inducible gene
control [25]. The control of eukaryotic gene transcription involves
positive/negative regulatory mechanisms, and various transcrip-
tion factors (primarily C/EBPs) have been reported to modulate
mRNA expression of A-SAA [1]. Several lines of evidence prompted
us to study expression of rSAA4 as well as its potential transcrip-
tional inducers, namely C/EBP. First, when treated with LPS, Saa1
and Saa2 mRNA levels were not upregulated in the liver of C/
EBPa-deﬁcient compared to wild-type mice [26]. Second, speciﬁc
disruption of hepatic C/EBPa in mice led to an almost complete
reduction of Saa4 mRNA compared with that observed in ﬂoxed-
mice [22]. Third, NF-jB- and C/EBP-like transcription factors act
as primary inducers of rSAA1 mRNA in the liver [20,21].
Although NF-jB binding sites are present in the promoter
region of rSAA4, we focussed on C/EBP-binding sites. Using speciﬁc
deletions in the promoter region, we identiﬁed three most proxi-
mal C/EBP-elements (between 888 and 1167 bp) that mediate
expression of rSAA4 in McA-RH7777 cells. Members of the C/EBP
family act as pivotal regulators of cellular differentiation, terminal
function, and response to inﬂammatory insults due to cytokine
activation. Although IL-6 (in contrast to other cytokines) promotes
rSAA4 expression in rat hepatoma cells even at early time points
(Fig. 3A), mRNA levels of individual members of the C/EBP-family
(C/EBPa and C/EBPb) were not affected (Supplemental Fig. II). This
raises the possibility that NF-jB could act in concert with C/EBP
to promote rSAA4 activation. Alternatively, transcription factor
YY1 may modulate rSAA4 transcription by binding to a site over-
lapping with the NF-jB-binding site [27]. AP-2 acts as a negative
regulator in extrahepatic tissues but promotes liver-speciﬁc rSAA1
expression [28]; in addition, a proximal AP-2 site in combination
with the NF-jB-binding site is essential for rSAA1 promoter activity
[25]. Whether these different modes of action, as previously
reported for rSAA1 [27], are also operative for rSAA4 is currently
unknown. However, our data showing even stronger Luciferase
activation with a short construct devoid of the three proximal C/
EBP-sites (not shown) and decreased activity with construct D
(containing all three C/EBP-sites plus additional 1000 bp)compared to construct C (containing only two C/EBP-sites) argue
for the involvement of additional activators and repressors,
respectively.
To sum up, we demonstrate for the ﬁrst time the presence of a
novel member of the SAA4 family on mRNA and protein level, pre-
viously not identiﬁed in the rat. The rSAA4 protein is expressed in
the liver as a non-glycosylated protein, comparable to mice.
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